PENTAX Medical introduces improved forceps for better control

HOYA Group PENTAX Medical has released the latest in flexible forceps for blood control during endoscopic procedures. The HemoStat WideCup offers easy control with better grip and less handling power.

The device, which was presented at the JDDW 2016 Congress in Japan, is used in minimally invasive procedures along with other therapeutic devices. As a part of the minimally invasive procedure process, which has been gaining traction all around the surgical space for its faster recovery time and low cost, the forceps improve upon current tools for more effective care. The forceps have a wider cup at 5.8 mm compared to the conventional 4 mm for better gripping of the bleeding point as well as having 30 to 40 percent less handling power.

"PENTAX Medical is committed to strengthening our endoscopic therapy portfolio to support better patient care. The HemoStat WideCup is a highly innovative hemostasis device designed to greatly simplify the control of bleeding," said Gerald W. Bottero, Global President, PENTAX Medical.  'We are confident the HemoStat WideCup sets a new standard for precise, efficient and safer endoscopic therapy, and will further support global growth of early screening and treatment of gastric cancer. We are committed to propagate and further develop this procedure."

 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.